BioCryst shares fall 50% after Phase III study meets primary endpoint

North Carolina, USA-based rare disease specialist BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced results from its Phase III APeX-2 trial of the investigational hereditary angioedema (HAE) therapy BCX7353.

While the trial met its primary endpoint for both dose levels, the level of impact in terms of preventing HAE attacks was not enough to impress analysts.

Half of people on the higher dose experienced a 70% reduction in the HAE attack rate compared to baseline, compared to 15% of those on placebo.